Author:
Nielsen Sarah M.,De Simone Lenika M.,Olopade Olufunmilayo I.
Reference35 articles.
1. Abeliovich, D., Kaduri, L., Lerer, I., Weinberg, N., Amir, G., Sagi, M., et al. (1997). The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. American Journal of Human Genetics, 60(3), 505–514.
2. Daly, M. B., Pilarski, R., Berry, M., Buys, S. S., Farmer, M., Friedman, S., et al. (2017). NCCN guidelines insights: genetic/familial high-risk assessment: breast and ovarian, version 2.2017. Journal of the National Comprehensive Cancer Network, 15(1), 9–20.
3. Desmond, A., Kurian, A. W., Gabree, M., Mills, M. A., Anderson, M. J., Kobayashi, Y., et al. (2015). Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment. JAMA Oncology, 1(7), 943–951.
https://doi.org/10.1001/jamaoncol.2015.2690
.
4. Domchek, S. M., Friebel, T. M., Singer, C. F., Evans, D. G., Lynch, H. T., Isaacs, C., et al. (2010). Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA, 304(9), 967–975.
https://doi.org/10.1001/jama.2010.1237
.
5. Easton, D. F., Pharoah, P. D., Antoniou, A. C., Tischkowitz, M., Tavtigian, S. V., Nathanson, K. L., et al. (2015). Gene-panel sequencing and the prediction of breast-cancer risk. The New England Journal of Medicine, 372(23), 2243–2257.
https://doi.org/10.1056/NEJMsr1501341
.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献